Clinical Trial

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-09-23; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2024-04-17
Trial Details
NCT Number NCT06063486
Lead Sponsor University of Southern California
Collaborators: National Cancer Institute (NCI)
Conditions Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis, Polycythemia Vera
Enrollment 30 participants
Start Date 2024-03-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-27